TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan
Brief Summary: This study is an evaluation of the benefit of adding artesunate to existing first and second line antimalarial therapies in Pakistan.

A placebo controlled trial was carried out to assess two potential benefits of Artesunate Combination Therapy (ACT): efficacy and potential for transmission reduction.


Options:
A: Arm Label: CQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ) | Arm Label: CQ+PQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ), Drug: primaquine (PQ) | Arm Label: CQ + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: Chloroquine (CQ) | Arm Label: SP; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP) | Arm Label: SP + PQ; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP), Drug: primaquine (PQ) | Arm Label: SP + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: sulphadoxine-pyrimethamine (SP) | Intervention Type: DRUG; Name: artesunate (AS); Assigned to Arm(s): CQ + AS, SP + AS | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine (SP); Assigned to Arm(s): SP, SP + AS, SP + PQ | Intervention Type: DRUG; Name: Chloroquine (CQ); Assigned to Arm(s): CQ, CQ + AS, CQ+PQ | Intervention Type: DRUG; Name: primaquine (PQ); Assigned to Arm(s): CQ+PQ, SP + PQ
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
C: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1
D: Arm Label: dihydroartemisinin-piperaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine | Arm Label: Dihydroartemisininpiperaquine primaquine; Type: ACTIVE_COMPARATOR; Interventions: Drug: dihydroartemisinin-piperaquine + primaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine; Assigned to Arm(s): dihydroartemisinin-piperaquine | Intervention Type: DRUG; Name: dihydroartemisinin-piperaquine + primaquine; Assigned to Arm(s): Dihydroartemisininpiperaquine primaquine

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Pseudo-randomised, Double-blinded Placebo-controlled Trial of Chloroquine or Sulphadoxine-pyrimethamine Alone or in Combination With Primaquine or Artesunate for the Treatment of Uncomplicated Falciparum Malaria in Pakistan
Brief Summary: This study is an evaluation of the benefit of adding artesunate to existing first and second line antimalarial therapies in Pakistan.

A placebo controlled trial was carried out to assess two potential benefits of Artesunate Combination Therapy (ACT): efficacy and potential for transmission reduction.


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg), Drug: Artesunate (day 1,2,3: 4 mg/kg), Drug: Primaquine-base (day 3: 0.75 mg/kg) | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablets | Intervention Type: DRUG; Name: Sulphadoxine-pyrimethamine (day 1: 500mg S&25mg P/20 kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Artesunate (day 1,2,3: 4 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Primaquine-base (day 3: 0.75 mg/kg); Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo tablets; Assigned to Arm(s): 2
B: Arm Label: CQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ) | Arm Label: CQ+PQ; Type: EXPERIMENTAL; Interventions: Drug: Chloroquine (CQ), Drug: primaquine (PQ) | Arm Label: CQ + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: Chloroquine (CQ) | Arm Label: SP; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP) | Arm Label: SP + PQ; Type: EXPERIMENTAL; Interventions: Drug: sulphadoxine-pyrimethamine (SP), Drug: primaquine (PQ) | Arm Label: SP + AS; Type: EXPERIMENTAL; Interventions: Drug: artesunate (AS), Drug: sulphadoxine-pyrimethamine (SP) | Intervention Type: DRUG; Name: artesunate (AS); Assigned to Arm(s): CQ + AS, SP + AS | Intervention Type: DRUG; Name: sulphadoxine-pyrimethamine (SP); Assigned to Arm(s): SP, SP + AS, SP + PQ | Intervention Type: DRUG; Name: Chloroquine (CQ); Assigned to Arm(s): CQ, CQ + AS, CQ+PQ | Intervention Type: DRUG; Name: primaquine (PQ); Assigned to Arm(s): CQ+PQ, SP + PQ
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Primaquine | Arm Label: Low dose primaquine (PQ1); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Intermediate dose primaquine (PQ2); Type: EXPERIMENTAL; Interventions: Drug: Primaquine | Arm Label: Reference dose primaquine (PQ-R); Type: ACTIVE_COMPARATOR; Interventions: Drug: Primaquine | Intervention Type: DRUG; Name: Primaquine; Assigned to Arm(s): Intermediate dose primaquine (PQ2), Low dose primaquine (PQ1), Placebo, Reference dose primaquine (PQ-R)
D: Arm Label: Arm 1; Type: EXPERIMENTAL; Interventions: Drug: chlorproguanil-dapsone-artesunate, Drug: chlorproguanil-dapsone | Intervention Type: DRUG; Name: chlorproguanil-dapsone-artesunate; Assigned to Arm(s): Arm 1 | Intervention Type: DRUG; Name: chlorproguanil-dapsone; Assigned to Arm(s): Arm 1

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Study of the Effect of Caloric Restriction and Exercise Training in Patients With Heart Failure and a Normal Ejection Fraction.(SECRET)
Brief Summary: The purpose of this study is to examine the effects of weight loss via hypocaloric diet, aerobic exercise training, combined hypocaloric diet and exercise training, and attention control in patients with heart failure and a normal ejection fraction (HFNEF) and body mass index greater than or equal to 30.


Options:
A: Arm Label: Exercise Training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Dietary Intervention; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Dietary Intervention | Arm Label: Attention control; Type: ACTIVE_COMPARATOR; Interventions: Other: Attention Control | Arm Label: Diet and Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise, Behavioral: Diet and exercise | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Diet and Exercise, Exercise Training | Intervention Type: DIETARY_SUPPLEMENT; Name: Dietary Intervention; Assigned to Arm(s): Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Diet and exercise; Assigned to Arm(s): Diet and Exercise | Intervention Type: OTHER; Name: Attention Control; Assigned to Arm(s): Attention control
B: Arm Label: High Intensity Exercise; Type: EXPERIMENTAL; Interventions: Behavioral: High Intensity Exercise | Arm Label: Moderate Continuous Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Moderate Continuous Exercise | Arm Label: Usual Care; Type: SHAM_COMPARATOR; Interventions: Behavioral: Usual Care | Intervention Type: BEHAVIORAL; Name: High Intensity Exercise; Assigned to Arm(s): High Intensity Exercise | Intervention Type: BEHAVIORAL; Name: Moderate Continuous Exercise; Assigned to Arm(s): Moderate Continuous Exercise | Intervention Type: BEHAVIORAL; Name: Usual Care; Assigned to Arm(s): Usual Care
C: Arm Label: Tai Chi; Type: EXPERIMENTAL; Interventions: Behavioral: 12-week Tai Chi Program | Arm Label: Heart Health Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: 12-week Education Program | Intervention Type: BEHAVIORAL; Name: 12-week Tai Chi Program; Assigned to Arm(s): Tai Chi | Intervention Type: BEHAVIORAL; Name: 12-week Education Program; Assigned to Arm(s): Heart Health Education
D: Arm Label: Walking intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Walking intervention | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Walking intervention; Assigned to Arm(s): Walking intervention

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial
Brief Summary: The purpose of this study is to determine if a new drug, varenicline, for smoking cessation is more effective than the standard nicotine replacement therapy aide currently used, "the patch" among smokers hospitalized with coronary heart disease.


Options:
A: Arm Label: Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Arm Label: No Incentives; Type: EXPERIMENTAL; Interventions: Behavioral: NH Medicaid Incentives Program | Intervention Type: BEHAVIORAL; Name: NH Medicaid Incentives Program; Assigned to Arm(s): Incentives, No Incentives
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
C: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation program TFC and activity tracker | Arm Label: Nicotine-free; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation program TFC-free and activity tracker | Arm Label: No-cig; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation program and activity tracker | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC and activity tracker; Assigned to Arm(s): Nicotine | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC-free and activity tracker; Assigned to Arm(s): Nicotine-free | Intervention Type: BEHAVIORAL; Name: Smoking cessation program and activity tracker; Assigned to Arm(s): No-cig
D: Arm Label: IQOS; Type: EXPERIMENTAL; Interventions: Device: IQOS | Arm Label: E-CIG; Type: ACTIVE_COMPARATOR; Interventions: Device: E-CIG | Intervention Type: DEVICE; Name: IQOS; Assigned to Arm(s): IQOS | Intervention Type: DEVICE; Name: E-CIG; Assigned to Arm(s): E-CIG

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial
Brief Summary: The purpose of this study is to determine if a new drug, varenicline, for smoking cessation is more effective than the standard nicotine replacement therapy aide currently used, "the patch" among smokers hospitalized with coronary heart disease.


Options:
A: Arm Label: Nicotine; Type: EXPERIMENTAL; Interventions: Behavioral: Smoking cessation program TFC and activity tracker | Arm Label: Nicotine-free; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation program TFC-free and activity tracker | Arm Label: No-cig; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation program and activity tracker | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC and activity tracker; Assigned to Arm(s): Nicotine | Intervention Type: BEHAVIORAL; Name: Smoking cessation program TFC-free and activity tracker; Assigned to Arm(s): Nicotine-free | Intervention Type: BEHAVIORAL; Name: Smoking cessation program and activity tracker; Assigned to Arm(s): No-cig
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: varenicline | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo tablet is made of lactose | Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): varenicline | Intervention Type: DRUG; Name: placebo tablet is made of lactose; Assigned to Arm(s): control group
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
D: Arm Label: Scheduled Gradual Reduction + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Varenicline | Arm Label: Scheduled Gradual Reduction + Placebo Drug; Type: EXPERIMENTAL; Interventions: Other: Scheduled Gradual Reduction + Placebo Drug | Arm Label: Basic Advice + Varenicline; Type: EXPERIMENTAL; Interventions: Other: Basic Advice + Varenicline | Arm Label: Basic Advice + Placebo Drug; Type: PLACEBO_COMPARATOR; Interventions: Other: Basic Advice + Placebo Drug | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Varenicline; Assigned to Arm(s): Scheduled Gradual Reduction + Varenicline | Intervention Type: OTHER; Name: Scheduled Gradual Reduction + Placebo Drug; Assigned to Arm(s): Scheduled Gradual Reduction + Placebo Drug | Intervention Type: OTHER; Name: Basic Advice + Varenicline; Assigned to Arm(s): Basic Advice + Varenicline | Intervention Type: OTHER; Name: Basic Advice + Placebo Drug; Assigned to Arm(s): Basic Advice + Placebo Drug

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial
Brief Summary: The purpose of this study is to determine if a new drug, varenicline, for smoking cessation is more effective than the standard nicotine replacement therapy aide currently used, "the patch" among smokers hospitalized with coronary heart disease.


Options:
A: Intervention Type: DRUG; Name: varenicline; Assigned to Arm(s): N/A
B: Arm Label: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline
C: Intervention Type: DRUG; Name: Varenicline tartrate; Assigned to Arm(s): N/A | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): N/A
D: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial
Brief Summary: The purpose of this study is to determine if a new drug, varenicline, for smoking cessation is more effective than the standard nicotine replacement therapy aide currently used, "the patch" among smokers hospitalized with coronary heart disease.


Options:
A: Arm Label: Varenicline & nicotine patches; Type: EXPERIMENTAL; Interventions: Drug: Varenicline, Drug: Nicotine patches | Arm Label: Varenicline & placebo patches; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: Placebo (nicotine patches) | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline & nicotine patches, Varenicline & placebo patches | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Varenicline & nicotine patches | Intervention Type: DRUG; Name: Placebo (nicotine patches); Assigned to Arm(s): Varenicline & placebo patches
B: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Intervention Type: DRUG; Name: bupropion (Wellbutrin); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial
Brief Summary: The purpose of this study is to determine if a new drug, varenicline, for smoking cessation is more effective than the standard nicotine replacement therapy aide currently used, "the patch" among smokers hospitalized with coronary heart disease.


Options:
A: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Behavioral: 5 A | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Behavioral: 3 A | Intervention Type: BEHAVIORAL; Name: 5 A; Assigned to Arm(s): 2 | Intervention Type: BEHAVIORAL; Name: 3 A; Assigned to Arm(s): 3
B: Arm Label: varenicline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline | Arm Label: Nicotine Patches only; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches | Arm Label: Nicotine Patches with Nicotine Inhaler; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nicotine patches, Drug: Nicotine Inhaler | Arm Label: varenicline with bupropion; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: Bupropion | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline, varenicline with bupropion | Intervention Type: DRUG; Name: Bupropion; Assigned to Arm(s): varenicline with bupropion | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Nicotine Patches only, Nicotine Patches with Nicotine Inhaler | Intervention Type: DRUG; Name: Nicotine Inhaler; Assigned to Arm(s): Nicotine Patches with Nicotine Inhaler
C: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
D: Arm Label: Chantix; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Nicotine patches | Arm Label: Chantix + Zyban; Type: EXPERIMENTAL; Interventions: Drug: Chantix, Drug: Zyban, Drug: Nicotine patches | Intervention Type: DRUG; Name: Chantix; Assigned to Arm(s): Chantix, Chantix + Zyban | Intervention Type: DRUG; Name: Zyban; Assigned to Arm(s): Chantix + Zyban | Intervention Type: DRUG; Name: Nicotine patches; Assigned to Arm(s): Chantix, Chantix + Zyban

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Varenicline Versus Transdermal Nicotine Patch for Smoking Cessation in Patients With Coronary Heart Disease: a Pilot Randomized Trial
Brief Summary: The purpose of this study is to determine if a new drug, varenicline, for smoking cessation is more effective than the standard nicotine replacement therapy aide currently used, "the patch" among smokers hospitalized with coronary heart disease.


Options:
A: Arm Label: Varenicline; Type: EXPERIMENTAL; Interventions: Drug: Varenicline | Arm Label: Transdermal Nicotine Patch; Type: EXPERIMENTAL; Interventions: Drug: Transdermal Nicotine Patch | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Varenicline | Intervention Type: DRUG; Name: Transdermal Nicotine Patch; Assigned to Arm(s): Transdermal Nicotine Patch
B: Arm Label: Placebo Control; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Placebo | Arm Label: Experimental: Varenicline; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Smoking cessation counseling, Drug: Varenicline | Intervention Type: BEHAVIORAL; Name: Smoking cessation counseling; Assigned to Arm(s): Experimental: Varenicline, Placebo Control | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo Control | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): Experimental: Varenicline
C: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Champix | Intervention Type: DRUG; Name: Champix; Assigned to Arm(s): Placebo
D: Arm Label: varenicline and buproprion SR; Type: ACTIVE_COMPARATOR; Interventions: Drug: Varenicline, Drug: bupropion SR | Arm Label: varenicline and placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Varenicline, Drug: placebo | Intervention Type: DRUG; Name: Varenicline; Assigned to Arm(s): varenicline and buproprion SR, varenicline and placebo | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): varenicline and placebo | Intervention Type: DRUG; Name: bupropion SR; Assigned to Arm(s): varenicline and buproprion SR

Answer: A